Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study

Acta Derm Venereol. 2016 Feb;96(2):251-2. doi: 10.2340/00015555-2209.
No abstract available

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Adalimumab / administration & dosage*
  • Adalimumab / adverse effects
  • Adult
  • Aged
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / adverse effects
  • Dermatologic Agents / administration & dosage*
  • Dermatologic Agents / adverse effects
  • Etanercept / administration & dosage*
  • Etanercept / adverse effects
  • Female
  • Humans
  • Italy
  • Male
  • Middle Aged
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Recurrence
  • Remission Induction
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Anti-Inflammatory Agents
  • Dermatologic Agents
  • Tumor Necrosis Factor-alpha
  • Adalimumab
  • Etanercept